C3 GLOMERULOPATHY

Clinical trials for C3 GLOMERULOPATHY explained in plain language.

Never miss a new study

Get alerted when new C3 GLOMERULOPATHY trials appear

Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 1 Completed 2

New drug survey for rare kidney disease: is fabhalta the answer?

Disease control Recruiting now

This study is tracking 50 people with C3 glomerulopathy, a rare kidney disease, who are taking the drug Fabhalta. Researchers want to see how safe the drug is and how well it controls the disease in everyday medical practice. The study will monitor infections, side effects, and k…

Matched conditions: C3 GLOMERULOPATHY

Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated May 17, 2026 02:01 UTC

C3 GLOMERULOPATHY

Get alerted when new C3 GLOMERULOPATHY trials appear

New drug survey for rare kidney disease: is fabhalta the answer?